5-(2-Aminopropyl)-2,3-dihydro-1H-indene (5-APDI), also known as indanylaminopropane (IAP), 2-aminopropylindane (2-API), indanametamine, and, incorrectly, as indanylamphetamine,[1] is an entactogen and psychedelic drug of the amphetamine family.

[2][3] It has been sold by online vendors through the Internet and has been encountered as a designer drug since 2003,[1] but its popularity and availability has diminished in recent years.

5-APDI appears to act as a potent and weakly selective serotonin releasing agent (SSRA) with IC50 values of 82 nM, 1,848 nM, and 849 nM for inhibiting the reuptake of serotonin, dopamine, and norepinephrine, respectively.

[2][3] It fully substitutes for MBDB but not amphetamine in trained animals, though it does produce disruption for the latter at high doses.

[2] 5-APDI has been classified as a class B drug under the Misuse of Drugs Act 1971 since 10 June 2014.